JPMorgan analyst Lucas Ferreira downgraded JBS S.A. to Neutral from Overweight with a price target of R$26, down from R$54. The analyst sees "faster and deeper than expected" deterioration of U.S. protein margins and expects normalized valuations in the mid-term.
Published first on TheFly
